Test Price
2,800 AED✅ Home Collection Available
FLNB Gene Atelosteogenesis Type 3 Next-Generation Sequencing (NGS) Genetic Test in UAE | AED 2,800
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity with ISO 9001:2015 accredited NGS processing. Full FLNB gene coverage using Next-Generation Sequencing for Atelosteogenesis Type 3 mutation detection.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM). Sample collection via whole blood, extracted DNA, or FTA card.
Clinical Guidance: Complimentary telephonic post-test clinical interpretation by a DHA-licensed Consultant Medical Geneticist (Dr. Lina Osama Zaki Quteineh, DHA ID: 9294403).
Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The FLNB Gene Atelosteogenesis Type 3 NGS Test is a comprehensive genetic analysis designed to detect pathogenic variants in the filamin B (FLNB) gene linked to autosomal dominant atelosteogenesis type 3, a rare skeletal dysplasia with characteristic limb shortening and skin dimpling. This advanced Next-Generation Sequencing assay covers all coding exons and exon‑intron boundaries, ensuring precise molecular diagnosis for differential diagnosis from other osteochondrodysplasias. The test is performed in a CAP‑accredited laboratory using Illumina® sequencing chemistry with a minimum depth of 50x coverage across the entire FLNB coding region.
| Feature | Our FLNB NGS Test | Closest Alternative |
|---|---|---|
| Sequencing Technology | Next‑Generation Sequencing (full gene coverage) | Sanger sequencing (limited to hotspot exons) |
| Turnaround Time | 14–21 working days | 6–8 weeks |
| Sample Collection | VIP Mobile Phlebotomy (8am–11pm, 7 days/week) | Clinic visit only |
| Price | AED 2,800 | AED 3,500 – 4,200 |
| Post‑Test Guidance | Free telephonic clinical interpretation by Consultant Medical Geneticist | None or report only |
Physician Insight & Safety Protocols
Dr. Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “This genetic test provides crucial diagnostic information for individuals and families investigating inherited skeletal dysplasias. A pathogenic variant in the FLNB gene confirms the clinical suspicion of atelosteogenesis type 3, but it is essential to correlate the genotype with radiographic findings and clinical phenotype. I strongly recommend pre‑test genetic counseling to discuss implications, inheritance patterns, and reproductive options. Post‑test, a board‑certified clinical geneticist should review the report in the context of the patient’s complete medical history.”
Medication Safety Advisory
⚠ Prescription Continuity
Do not alter or discontinue any prescribed medication without consulting your treating physician. Genetic test results are intended solely for diagnostic and counseling purposes and do not replace ongoing clinical management or pharmacological oversight.
Exclusion Criteria & Emergency Red Flags
Acute Medical Exclusions
- Recent blood transfusion (within 2 weeks) – may compromise DNA quality.
- Active chemotherapy affecting nucleated cell count.
- If you experience acute bone pain, sudden fractures, or respiratory distress, seek emergency medical care immediately. Genetic testing is not a substitute for urgent evaluation.
Patient FAQ & Clinical Guidance
1. What variants does the FLNB gene test detect?
The test detects all pathogenic and likely pathogenic variants within the FLNB coding exons and ±10 bp flanking intronic regions. This includes missense, nonsense, frameshift, and splice‑site mutations that lead to abnormal filamin B protein function. Approximately 85% of reported FLNB mutations are missense changes clustered in the actin‑binding domain or rod domain. The assay is designed to meet ACMG/AMP guidelines for variant classification.
2. How is the sample collected and what are the options?
Our VIP mobile phlebotomy team collects 2–3 ml of whole blood in an EDTA tube at your home, office, or hotel (daily 8 AM to 11 PM). Alternatively, a single drop of blood on an FTA card or previously extracted genomic DNA (≥1 μg) can be sent via secure courier. Cold‑chain transport to our ISO‑certified laboratory ensures sample integrity within 24 hours. No special preparation is required.
3. What should I do if my result is positive?
If the result is positive (pathogenic variant detected), schedule an appointment with a clinical geneticist as soon as possible. The geneticist will review the report, correlate it with clinical and radiographic findings, and discuss management, surveillance, and family screening. A positive result does not guarantee severe complications, but it warrants multidisciplinary follow‑up including pediatric orthopedics and dermatology when indicated. Pre‑test counseling is recommended to prepare for all possible outcomes.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Security: DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority (DHA) and complies fully with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and retained only for the duration required by local health regulations. Patient specimens are de‑identified before sequencing to ensure confidentiality.
Clinical Safety & Consent: This test is performed in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability. Informed consent is obtained prior to sample collection, and results are delivered only to the ordering physician or the patient with verified identity.
Clinical & Logistical Metadata
| Test Name | FLNB Gene Atelosteogenesis Type 3 Next-Generation Sequencing (NGS) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 14–21 working days |
| Sample Type / Matrix | Whole blood (EDTA), genomic DNA (≥1 μg), or dried blood spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina platform, whole gene coverage |
| ICD-10-CM Code | Q77.3 (Atelosteogenesis) |
| LOINC Code | 54236-7 (Gene FLNB sequencing) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians